The core purpose of the Value and Evidence Strategy team at Alnylam is to lead evidence generation and value demonstration activities through cross-functional collaboration with Clinical Development, Market Access, Market Insights, Regulatory Affairs, and other expertise areas. The Fellow will gain a thorough understanding of and hands on experience in health economics and outcomes research methodologies to scientifically evaluate a therapeutic’s potential economic, clinical, and humanistic impact. VESt’s goal is to ensure excellence in evidence generation so Alnylam’s innovative science can reach patients and healthcare systems.
Conduct evidence gap analysis and develop data generation strategy to communicate the value of products to internal and external stakeholders
Contribute to prospective and retrospective observational studies, cost effectiveness research, comparative effectiveness research, chart review studies, patient-reported outcomes research, and other studies with potential for publication
Conduct burden of illness studies and pharmacoeconomic analyses for use by healthcare decision makers
Develop and maintain peer/KOL relationships for clinical input into HEOR studies
About Alnylam Pharmaceuticals and Northeastern University
About the Fellowship Program:
Three years ago, Alnylam Pharmaceuticals partnered with Northeastern University to become the first Fellowship Program at a pre-commercial company. Since its inception, the Program has grown and continues to be an integral asset to all stakeholders. For the 2018 – 2020 recruitment cycle, the Fellowship Program is pleased to offer four 2-year positions in the followin...g expertise areas: Regulatory Affairs, Medical Affairs, Value and Evidence Strategy (VESt)/HEOR, and Medical Information. The first year, Fellows customize their experience with individualized elective rotations throughout various groups at Alnylam while remaining a vital member in their core expertise area. In the second year, Fellows focus on their primary function. Throughout the two years, Fellows also have responsibilities at Northeastern University, such as teaching PharmD students and participating in longitudinal research with faculty.
Since it was founded in 2002, Alnylam Pharmaceuticals has been committed to harnessing the power of RNA interference (RNAi) for treating rare conditions with high unmet medical need. Today, it is leading the translation of RNAi to a potential new class of innovative medicines to treat a wide range of diseases using its powerful, clinically validated approach. In 2015, the company issued its “Alnylam 2020” guidance for the advancement and commercialization of RNAi therapeutics in three Strategic Areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, and Hepatic Infectious Diseases and has the potential to launch multiple commercial products.
About Northeastern University
Northeastern University is a global, experiential, research university built on a tradition of engagement with the world, creating a distinctive approach to education and research. The School of Pharmacy is dedicated to excellence in pharmacy-related education, research, and service, including the provision of patient care. The Alnylam Pharmaceuticals and Northeastern University Fellowship Program provides a dynamic academic environment to guide and support Fellows toward successful careers in the biopharmaceutical industry and offers them the opportunity to gain a wide range of large group didactic and small group practice-related teaching experiences.